![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KLF6 |
Gene summary for KLF6 |
![]() |
Gene information | Species | Human | Gene symbol | KLF6 | Gene ID | 1316 |
Gene name | Kruppel like factor 6 | |
Gene Alias | BCD1 | |
Cytomap | 10p15.2 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | D3GC14 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1316 | KLF6 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 5.73e-07 | 1.22e+00 | -0.2126 |
1316 | KLF6 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 1.45e-08 | 2.36e+00 | -0.2247 |
1316 | KLF6 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 1.62e-10 | 1.13e+00 | -0.1433 |
1316 | KLF6 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 5.68e-10 | 9.65e-01 | -0.1833 |
1316 | KLF6 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 1.71e-06 | 1.51e+00 | -0.23 |
1316 | KLF6 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 3.66e-06 | 1.83e+00 | -0.23 |
1316 | KLF6 | 047563_1562-all-cells | Human | Prostate | BPH | 2.16e-11 | -4.13e-01 | 0.0791 |
1316 | KLF6 | 048752_1579-all-cells | Human | Prostate | BPH | 1.24e-05 | -8.76e-02 | 0.1008 |
1316 | KLF6 | 052095_1628-all-cells | Human | Prostate | BPH | 9.42e-14 | -4.62e-01 | 0.1032 |
1316 | KLF6 | 052097_1595-all-cells | Human | Prostate | BPH | 3.88e-03 | -2.76e-01 | 0.0972 |
1316 | KLF6 | 052099_1652-all-cells | Human | Prostate | BPH | 3.88e-05 | -3.44e-01 | 0.1038 |
1316 | KLF6 | Dong_P1 | Human | Prostate | Tumor | 3.07e-27 | -2.12e-01 | 0.035 |
1316 | KLF6 | Dong_P3 | Human | Prostate | Tumor | 2.86e-07 | -2.99e-01 | 0.0278 |
1316 | KLF6 | Dong_P5 | Human | Prostate | Tumor | 3.70e-54 | -8.90e-01 | 0.053 |
1316 | KLF6 | P7 | Human | Prostate | Tumor | 3.20e-11 | 1.05e+00 | -0.1025 |
1316 | KLF6 | P9 | Human | Prostate | Tumor | 6.25e-17 | 1.57e+00 | -0.0285 |
1316 | KLF6 | P10 | Human | Prostate | Tumor | 6.49e-14 | 1.39e+00 | -0.0902 |
1316 | KLF6 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 1.83e-02 | -1.07e-01 | 0.159 |
1316 | KLF6 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 2.16e-11 | -5.46e-01 | 0.1608 |
1316 | KLF6 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 1.42e-07 | -7.13e-01 | 0.1604 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19031313 | Breast | Precancer | mononuclear cell differentiation | 43/1080 | 426/18723 | 2.61e-04 | 3.84e-03 | 43 |
GO:0030098 | Breast | Precancer | lymphocyte differentiation | 36/1080 | 374/18723 | 1.85e-03 | 1.81e-02 | 36 |
GO:190313111 | Breast | IDC | mononuclear cell differentiation | 51/1434 | 426/18723 | 9.81e-04 | 1.11e-02 | 51 |
GO:19031312 | Breast | DCIS | mononuclear cell differentiation | 51/1390 | 426/18723 | 4.88e-04 | 6.40e-03 | 51 |
GO:19031314 | Cervix | CC | mononuclear cell differentiation | 76/2311 | 426/18723 | 5.66e-04 | 5.42e-03 | 76 |
GO:00300981 | Cervix | CC | lymphocyte differentiation | 63/2311 | 374/18723 | 6.21e-03 | 3.52e-02 | 63 |
GO:190313112 | Cervix | HSIL_HPV | mononuclear cell differentiation | 29/737 | 426/18723 | 3.10e-03 | 2.84e-02 | 29 |
GO:0042113 | Cervix | HSIL_HPV | B cell activation | 24/737 | 334/18723 | 3.48e-03 | 3.14e-02 | 24 |
GO:190313121 | Cervix | N_HPV | mononuclear cell differentiation | 24/534 | 426/18723 | 1.27e-03 | 1.40e-02 | 24 |
GO:00421131 | Cervix | N_HPV | B cell activation | 18/534 | 334/18723 | 7.67e-03 | 4.96e-02 | 18 |
GO:1903131 | Colorectum | FAP | mononuclear cell differentiation | 79/2622 | 426/18723 | 5.00e-03 | 3.33e-02 | 79 |
GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
GO:19031311 | Lung | IAC | mononuclear cell differentiation | 66/2061 | 426/18723 | 2.63e-03 | 2.44e-02 | 66 |
GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
GO:00300983 | Oral cavity | OSCC | lymphocyte differentiation | 179/7305 | 374/18723 | 2.74e-04 | 1.74e-03 | 179 |
GO:190313114 | Oral cavity | EOLP | mononuclear cell differentiation | 88/2218 | 426/18723 | 1.07e-07 | 3.61e-06 | 88 |
GO:003009812 | Oral cavity | EOLP | lymphocyte differentiation | 76/2218 | 374/18723 | 1.50e-06 | 3.55e-05 | 76 |
GO:00421132 | Oral cavity | EOLP | B cell activation | 61/2218 | 334/18723 | 3.68e-04 | 3.35e-03 | 61 |
GO:190313122 | Oral cavity | NEOLP | mononuclear cell differentiation | 77/2005 | 426/18723 | 2.80e-06 | 6.41e-05 | 77 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
KLF6 | BAS | Skin | Healthy | NEAT1,IRF2BP2,CEBPB, etc. | 2.01e-01 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KLF6 | SNV | Missense_Mutation | c.240G>C | p.Lys80Asn | p.K80N | Q99612 | protein_coding | tolerated(0.31) | benign(0) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
KLF6 | SNV | Missense_Mutation | c.394G>A | p.Glu132Lys | p.E132K | Q99612 | protein_coding | tolerated(0.22) | benign(0.026) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
KLF6 | SNV | Missense_Mutation | rs773677946 | c.736N>A | p.Glu246Lys | p.E246K | Q99612 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
KLF6 | SNV | Missense_Mutation | c.660N>A | p.His220Gln | p.H220Q | Q99612 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
KLF6 | SNV | Missense_Mutation | c.347N>G | p.Ser116Cys | p.S116C | Q99612 | protein_coding | tolerated(0.11) | benign(0.01) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
KLF6 | SNV | Missense_Mutation | novel | c.269N>A | p.Leu90His | p.L90H | Q99612 | protein_coding | tolerated(0.21) | benign(0.174) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
KLF6 | SNV | Missense_Mutation | rs773677946 | c.736N>A | p.Glu246Lys | p.E246K | Q99612 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CK-4952-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
KLF6 | SNV | Missense_Mutation | c.392G>A | p.Gly131Asp | p.G131D | Q99612 | protein_coding | tolerated(0.17) | benign(0.343) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
KLF6 | SNV | Missense_Mutation | rs753610916 | c.232N>A | p.Glu78Lys | p.E78K | Q99612 | protein_coding | tolerated(0.29) | benign(0) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
KLF6 | SNV | Missense_Mutation | novel | c.590N>T | p.Arg197Met | p.R197M | Q99612 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |